All Type of News
Samsung Mulsan seeking growth engine from pharmaceutical logistics business
There is a floating rumor attracted keen interests to the public that Samsung Mulsan, the top conglomerate group in Korea, may step into the pharmaceutical industry.
Such a rumor has chilled the local wholesaling i...
NHIC, Daewon poles apart on medicine negotiation
The National Health Insurance Corporation and Daewon Pharm remain far apart in their negotiations over the price evaluation of home-grown Peluvi tablets (felubiprofen), new NSAID (nonsteroidal anti-inflammatory drug) ...
Hospitals and pharmacies to face punishment over illegal request
The government will crack down on some hospitals and clinics for their illegal requests for health insurance benefits, according to the Ministry of Health, Welfare and Family Affairs.
The ministry said on July 29 t...
Vacant posts grip KFDA
The Korea Food and Drug Administration is finding itself in the grip of a vortex of vacant posts of high-ranking officials due to the government’ plan to disband six regional KFDA agencies.
The KFDA predicts that t...
GCC’s sales up 12.5% in second quarter
Green Cross Corporation said on July 29 that its second-quarter sales gained 12.5 percent to 124.4 billion won from a year earlier, while operating profit increased 19.8 percent to 18.7 billion won.
Net income amou...
Pricing criteria for chemically modified drugs eyed
The government plans to announce the pricing criteria of chemically modified drugs in the middle of next month, according to the Ministry of Health, Welfare and Family Affairs.
The ministry said that after the phar...
Ildong to build W50 bil. plantIldong Pharm says it will invest about 50.0 billion won to build a cGMP plant producing cephalosporin antibiotics and antineoplastic agents by July next year.
The plant will ...
|
Whanin to market quetiapine 1000 mg
Whanin Pharm says it will sell quetiapine 1000 mg in addition to its strengths of 25 mg and 200 mg from August 1.
Whanin’s first version of antipsychotic Seroquel generic would be a major setback for AstraZeneca Ko...
Domestic pharmaceutical firms to nurture cGMP professionals
Korean companies will be able to bet on the possibility of mutual recognition arrangement (MRA) on generic drugs following the free trade agreement (FTA) ratification with the United States.
However, there are gro...
NKBio files patent application for new atherosclerosis treatment
NKBio says it has filed its domestic patent application for cytokeratin-1 compound, a potential drug candidate in the prevention and treatment of atherosclerosis.
The company notes that cytokeratin-1, which is asso...
